Laboratorios Farmaceuticos Rovi
Market Cap
€1.6b
Last Updated
2020/08/06 21:51 UTC
Data Sources
Company Financials +
Executive Summary
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential with excellent balance sheet.
Share Price & News
How has Laboratorios Farmaceuticos Rovi's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ROVI has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-2.4%
ROVI
-1.7%
ES Pharmaceuticals
-1.8%
ES Market
1 Year Return
30.1%
ROVI
11.1%
ES Pharmaceuticals
-17.7%
ES Market
Return vs Industry: ROVI exceeded the Spanish Pharmaceuticals industry which returned 11.1% over the past year.
Return vs Market: ROVI exceeded the Spanish Market which returned -17.7% over the past year.
Shareholder returns
| ROVI | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.4% | -1.7% | -1.8% |
| 30 Day | 11.5% | -5.0% | -5.9% |
| 90 Day | 8.9% | -3.5% | 4.1% |
| 1 Year | 30.1%30.1% | 14.7%11.1% | -15.1%-17.7% |
| 3 Year | 80.7%79.0% | 30.3%15.1% | -23.5%-30.6% |
| 5 Year | 122.4%116.5% | 23.5%2.2% | -18.9%-32.0% |
Price Volatility Vs. Market
How volatile is Laboratorios Farmaceuticos Rovi's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Laboratorios Farmaceuticos Rovi, S.A. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year1 week ago | Simply Wall St
If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late1 month ago | Simply Wall St
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 49% Below Their Intrinsic Value EstimateValuation
Is Laboratorios Farmaceuticos Rovi undervalued compared to its fair value and its price relative to the market?
29.45x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ROVI (€28.1) is trading above our estimate of fair value (€21.84)
Significantly Below Fair Value: ROVI is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ROVI is poor value based on its PE Ratio (29.4x) compared to the XE Pharmaceuticals industry average (22.7x).
PE vs Market: ROVI is poor value based on its PE Ratio (29.4x) compared to the Spanish market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: ROVI is good value based on its PEG Ratio (1x)
Price to Book Ratio
PB vs Industry: ROVI is overvalued based on its PB Ratio (4.4x) compared to the XE Pharmaceuticals industry average (3.3x).
Next Steps
Future Growth
How is Laboratorios Farmaceuticos Rovi forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
30.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ROVI's forecast earnings growth (30.6% per year) is above the savings rate (1.3%).
Earnings vs Market: ROVI's earnings (30.6% per year) are forecast to grow faster than the Spanish market (30.4% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ROVI's revenue (14% per year) is forecast to grow faster than the Spanish market (5.7% per year).
High Growth Revenue: ROVI's revenue (14% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ROVI's Return on Equity is forecast to be high in 3 years time (23.2%)
Next Steps
Past Performance
How has Laboratorios Farmaceuticos Rovi performed over the past 5 years?
13.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ROVI has a high level of non-cash earnings.
Growing Profit Margin: ROVI's current net profit margins (13.3%) are higher than last year (7.9%).
Past Earnings Growth Analysis
Earnings Trend: ROVI's earnings have grown by 13.5% per year over the past 5 years.
Accelerating Growth: ROVI's earnings growth over the past year (98.3%) exceeds its 5-year average (13.5% per year).
Earnings vs Industry: ROVI earnings growth over the past year (98.3%) exceeded the Pharmaceuticals industry 10%.
Return on Equity
High ROE: ROVI's Return on Equity (15%) is considered low.
Next Steps
Financial Health
How is Laboratorios Farmaceuticos Rovi's financial position?
Financial Position Analysis
Short Term Liabilities: ROVI's short term assets (€351.5M) exceed its short term liabilities (€111.6M).
Long Term Liabilities: ROVI's short term assets (€351.5M) exceed its long term liabilities (€80.0M).
Debt to Equity History and Analysis
Debt Level: ROVI's debt to equity ratio (15%) is considered satisfactory.
Reducing Debt: ROVI's debt to equity ratio has reduced from 22.1% to 15% over the past 5 years.
Debt Coverage: ROVI's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: ROVI's interest payments on its debt are well covered by EBIT (59.6x coverage).
Balance Sheet
Next Steps
Dividend
What is Laboratorios Farmaceuticos Rovi current dividend yield, its reliability and sustainability?
0.62%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ROVI's dividend (0.62%) isn’t notable compared to the bottom 25% of dividend payers in the Spanish market (2.5%).
High Dividend: ROVI's dividend (0.62%) is low compared to the top 25% of dividend payers in the Spanish market (6.42%).
Stability and Growth of Payments
Stable Dividend: ROVI is not paying a notable dividend for the Spanish market, therefore no need to check if payments are stable.
Growing Dividend: ROVI is not paying a notable dividend for the Spanish market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: ROVI is not paying a notable dividend for the Spanish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ROVI's dividend in 3 years as they are not forecast to pay a notable one for the Spanish market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
10.9yrs
Average management tenure
CEO
Juan López-Belmonte Encina
3.58yrs
Tenure
€541,000
Compensation
Mr. Juan López-Belmonte Encina has been Chief Executive Officer of Laboratorios Farmaceuticos ROVI, S.A. since October 2007. Mr. Encina has been with Laboratorios Farmaceuticos ROVI since 1994 and served a ...
CEO Compensation Analysis
Compensation vs Market: Juan's total compensation ($USD640.84K) is below average for companies of similar size in the Spanish market ($USD950.71K).
Compensation vs Earnings: Juan's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.58yrs | €541.00k | no data | |
| First Deputy Chairman & Head of Corporate Development | 4.75yrs | €416.00k | no data | |
| Second Deputy Chairman & CFO | 4.75yrs | €417.00k | no data | |
| Legal Department Manager | no data | no data | no data | |
| Director of Sales | 10.92yrs | no data | no data | |
| Marketing Manager | no data | no data | no data | |
| Human Resources Manager | no data | no data | no data | |
| Secretary | no data | no data | no data | |
| Deputy Secretary | 2.58yrs | no data | no data |
10.9yrs
Average Tenure
Experienced Management: ROVI's management team is seasoned and experienced (10.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.58yrs | €541.00k | no data | |
| First Deputy Chairman & Head of Corporate Development | 4.75yrs | €416.00k | no data | |
| Second Deputy Chairman & CFO | 4.75yrs | €417.00k | no data | |
| Chairman | no data | €150.00k | no data | |
| Independent Director | 5.17yrs | €60.00k | no data | |
| Adviser | 1.25yrs | €39.00k | no data | |
| Independent Director | 0.67yr | €2.00k | no data |
4.8yrs
Average Tenure
Experienced Board: ROVI's board of directors are considered experienced (4.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Laboratorios Farmaceuticos Rovi, S.A.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Laboratorios Farmaceuticos Rovi, S.A.
- Ticker: ROVI
- Exchange: BME
- Founded: 1946
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: €1.557b
- Shares outstanding: 55.39m
- Website: https://www.rovi.es
Number of Employees
Location
- Laboratorios Farmaceuticos Rovi, S.A.
- Calle JuliAn Camarillo, 35
- Madrid
- Madrid
- Spain
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ROVI | BME (Bolsas y Mercados Espanoles) | Yes | Nominative Shares | ES | EUR | Dec 2007 |
| 0ILL | LSE (London Stock Exchange) | Yes | Nominative Shares | GB | EUR | Dec 2007 |
| 41L | DB (Deutsche Boerse AG) | Yes | Nominative Shares | DE | EUR | Dec 2007 |
| ROVIE | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Nominative Shares | GB | EUR | Dec 2007 |
| ROVI N | BMV (Bolsa Mexicana de Valores) | Yes | Nominative Shares | MX | MXN | Dec 2007 |
Biography
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company also d ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/08/06 21:51 |
| End of Day Share Price | 2020/08/06 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.